Reach Us +1-217-403-9671
Bioavailability & Bioequivalence: Pharmacokinetic Principles | 8235
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Bioavailability & Bioequivalence: Pharmacokinetic principles

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Abdus Samad

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

B iological products or medicines are therapeutic agents which are produced using a living system or organism. Access to these life-saving biological products is limited because of their expensive costs. Patents of the early biological products will be soon expired in the next few years. Th is allows other biopharmaceutical/biotech companies to manufacture the generic versions of the biological products, which are referred to the follow-on biological products by the United States Food and Drug Administration (FDA) or biosimilar medicinal products by the European Medicine Agency (EMA) of the European Union (EU). Competition of cost-eff ective follow- on biological products with equivalent effi cacy and safety can cut down the costs and hence increase patients? access to the much needed biological pharmaceuticals. Unlike the conventional pharmaceuticals of small molecular, the complexity and heterogeneity of the molecular structure, complicated manufacturing process, diff erent analytical methods, and possibility of severe immunogenecity reactions make evaluation of equivalence (similarity) between the biosimilar products and their corresponding innovator product a great challenge for both scientifi c community and regulatory agencies. In this paper, we will provide an overview of the current regulatory requirements for approval of biosimilar products. A review of current criteria for evaluation of bioequivalence for the traditional chemical generic products is provided. In addition, statistical considerations including design, criteria, fundamental biosimilar assumption and statistical methods are proposed. Th e possibility of using genomic data in evaluation of biosimilar products is also explored
Shein-Chung Chow, Ph.D. is a Professor at the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA. Dr. Chow is currently the Editor-in-Chief of the Journal of Biopharmaceutical Statistics and Biostatistics Book Series of Chapman and Hall/CRC Press. He is a Fellow of the American Statistical Association. Dr. Chow is the author or co-author over 200 methodology papers and 18 books, which include Design and Analysis of Bioavailability and Bioequivalence Studies and Sample Size Calculation in Clinical Research. Dr. Chow received his Ph.D. in statistics from the University of Wisconsin, Madison, Wisconsin, USA